Fig. 4: PRMT3 is required for GBM cell migration.
From: PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism
A, B Scratch assays (upper) and quantification (bottom) of Ctrl and PRMT3-KD U87 (A) and U251 (B) cell lines. C Representative images of migrating cells of U87 or U251 treated with Ctrl and PRMT3 shRNA with 48 hr followed by the Boyden chamber invasion assay for 72 hours. Area per field, 1 mm2. Scale bar, 100 μm (upper). Quantification of invasive cells of U87 or U251Ctrl and PRMT3 KD cells (bottom). D Upper, representative images of migrating cells of U87 or U251 transduced with Ctrl and PRMT3-OE following 72 hours in the Boyden chamber invasion assay; Bottom, Quantification of invasive cells. Area per field, 1 mm2. Scale bar, 50 μm. Data are presented as means ± SEM; n = 3 independent experiments; *p < 0.05; **p < 0.01; ***p < 0.001; two-tailed unpaired Student t-test (in D) or one-way ANOVA with multiple comparison test (in A–C).
